NCT02464163View on ClinicalTrials.gov

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

407

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Influenza

Interventions

BIOLOGICAL

Panblok

Intramuscular injection

BIOLOGICAL

rHA adjuvant

Intramuscular injection

Trial Locations (9)

13760

Regional Clinical Research, Inc., Endwell

31406

Meridian Clinical Research, Savannah

32720

Avail Clinical Research, DeLand

36608

Coastal Clinical Research, Mobile

44122

Rapid Medical Research, Inc., Cleveland

68164

Meridian Clinical Research, Omaha

76135

Benchmark Research - Fort Worth, Fort Worth

78705

Benchmark Reseach, Austin

84124

Jean Brown Research, Salt Lake City

All Listed Sponsors

lead

Protein Sciences Corporation

INDUSTRY

NCT02464163 - Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older | Biotech Hunter | Biotech Hunter